Microbot Medical Inc. Files S-1/A Amendment

TL;DR

<b>Microbot Medical Inc. has filed an S-1/A amendment, providing updated corporate and financial information.</b>

AI Summary

Microbot Medical Inc. (MBOT) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. Microbot Medical Inc. filed an S-1/A amendment on January 22, 2024. The company's principal executive offices are located at 25 Recreation Park Dr, Suite 108, Hingham, MA 02043. The business phone number listed is 908-938-5561. The company was formerly known as STEMCELLS INC and CYTOTHERAPEUTICS INC/DE. The fiscal year end for Microbot Medical Inc. is December 31st.

Why It Matters

For investors and stakeholders tracking Microbot Medical Inc., this filing contains several important signals. This filing indicates ongoing corporate actions and potential future offerings or disclosures by Microbot Medical Inc. The amendment provides updated details on the company's structure, former names, and operational address, which are crucial for investors and stakeholders to track corporate developments.

Risk Assessment

Risk Level: low — Microbot Medical Inc. shows low risk based on this filing. The filing is an amendment (S-1/A) which typically updates previously filed information rather than introducing entirely new material risks, suggesting a lower immediate risk profile based solely on this document type.

Analyst Insight

Monitor future filings for specific details regarding the purpose of this S-1/A amendment, such as updated financial data or offering plans.

Key Numbers

• 2024-01-22 — Filing Date (S-1/A filing date)
• 1231 — Fiscal Year End (Fiscal year end date)

Key Players & Entities

• Microbot Medical Inc. (company) — Filer name
• 25 Recreation Park Dr Suite 108 (location) — Business address
• Hingham, MA (location) — Business address city and state
• 908-938-5561 (phone) — Business phone
• STEMCELLS INC (company) — Former company name
• CYTOTHERAPEUTICS INC/DE (company) — Former company name

Forward-Looking Statements

• Microbot Medical Inc. will proceed with a securities offering based on this amended S-1/A filing. (Microbot Medical Inc.) — medium confidence, target: 2024-12-31

FAQ

Industry Context

Microbot Medical Inc. operates in the medical instruments and apparatus industry, specifically focusing on surgical applications.

Regulatory Implications

The S-1/A filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and business descriptions.
2. Track future SEC filings from Microbot Medical Inc. for any material updates or disclosures.
3. Research the company's historical performance and market position within the surgical instruments sector.

Key Dates

• 2024-01-22: S-1/A Filing — Amendment to registration statement filed by Microbot Medical Inc.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates rather than a new initial filing.

Key Financial Figures

• $0.01 — o 1,769,966 shares of our common stock, $0.01 par value per share, representing share
• $1.34 — stock on the Nasdaq Capital Market was $1.34. Investing in our common stock involv
• $6,750,000 b — nt or settlement for some or all of the $6,750,000 being litigated, will have a material adv
• $2.20 — 's Common Stock at an exercise price of $2.20 per share, issued on October 25, 2022,
• $2.075 — 's Common Stock at an exercise price of $2.075 per share, issued on June 6, 2023, and
• $3.19 — 's Common Stock at an exercise price of $3.19 per share issued on June 26, 2023 (the
• $1.62 — Stock, at a reduced exercised price of $1.62 per share, in consideration for the Com
• $1.50 — 's Common Stock at an exercise price of $1.50 per share. The Inducement Investment Op
• $2.73 million — s from the transaction of approximately $2.73 million. The Company engaged H.C. Wainwright
• $60,000 — tions. The Company also paid Wainwright $60,000 for non-accountable expenses, and $15,9
• $15,950 — 0,000 for non-accountable expenses, and $15,950 for clearing fees. The Company also agr
• $2.025 — s except for an exercise price equal to $2.025 per share. Further, pursuant to the Eng

Filing Documents

• forms-1a.htm (S-1/A) — 2546KB
• ex4-11.htm (EX-4.11) — 136KB
• ex4-12.htm (EX-4.12) — 135KB
• ex5-1.htm (EX-5.1) — 11KB
• ex10-32.htm (EX-10.32) — 63KB
• ex23-1.htm (EX-23.1) — 3KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• form10-k_001.jpg (GRAPHIC) — 11KB
• form10-k_002.jpg (GRAPHIC) — 52KB
• ex5-1_001.jpg (GRAPHIC) — 27KB
• 0001493152-24-003322.txt (&nbsp;) — 9164KB
• mbot-20230930.xsd (EX-101.SCH) — 58KB
• mbot-20230930_cal.xml (EX-101.CAL) — 66KB
• mbot-20230930_def.xml (EX-101.DEF) — 222KB
• mbot-20230930_lab.xml (EX-101.LAB) — 365KB
• mbot-20230930_pre.xml (EX-101.PRE) — 301KB
• forms-1a_htm.xml (XML) — 1426KB

BUSINESS

BUSINESS 39 BOARD OF DIRECTORS AND MANAGEMENT 53 EXECUTIVE COMPENSATION 58 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 63 SECURITY 64

DILUTION

DILUTION 65 SELLING STOCKHOLDERS 65 PLAN OF DISTRIBUTION 66 DESCRIPTION OF CAPITAL STOCK 67 LEGAL MATTERS 70 EXPERTS 70 WHERE YOU CAN FIND MORE INFORMATION 70 FINANCIAL F-1 ABOUT THIS PROSPECTUS You should rely only on the information that we have provided in this prospectus and any prospectus supplement that we may authorize to be provided to you. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any prospectus supplement that we may authorize to be provided to you. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information in this prospectus and any prospectus supplement is accurate only as of the date on the cover of the document, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We urge you to carefully read this prospectus and any prospectus supplement, together with the information as described under the heading "Where You Can Find More Information." Unless the context indicates otherwise, as used in this prospectus, the terms "we," "us," "our," the "Company" and "Microbot" refer to Microbot Medical Inc., including our directly and indirectly wholly owned subsidiary. Unless the context otherwise requires, the historical business, financial statements and operations of Microbot include Microbot Medical Ltd., an Israeli corporation ("Microbot Israel") which became a wholly-owned subsidiary of the Company on November 28, 2016. We own or have rights to various U.S. federal trademark registrations and applications, and unregistered trademarks and servicemarks, including LIBERTY . All other

View Full Filing

View this S-1/A filing on SEC EDGAR